Analyst Activity – Canaccord Genuity Reiterates Buy on Cardiome Pharma Corporation (NASDAQ:CRME)

8

Analyst Ratings For Cardiome Pharma Corporation (NASDAQ:CRME)

Today, Canaccord Genuity reiterated its Buy rating on Cardiome Pharma Corporation (NASDAQ:CRME) with a price target of $8.00.

There are 1 hold rating, 5 buy ratings on the stock.

The current consensus rating on Cardiome Pharma Corporation (NASDAQ:CRME) is Buy (Score: 2.83) with a consensus target price of $6.65 per share, a potential 41.49% upside.

Some recent analyst ratings include

  • 7/17/2017-Canaccord Genuity Reiterated Rating of Buy.
  • 12/22/2016-Leerink Swann initiated coverage with a Outperform rating.
  • 11/9/2016-Bloom Burton Reiterated Rating of Buy.
  • 10/12/2016-Mackie Reiterated Rating of Speculative Buy .
  • 8/15/2016-Brean Capital Reiterated Rating of Buy.
  • 8/14/2015-LB Securities Reiterated Rating of Buy.

Dividend information for Cardiome Pharma Corporation (NASDAQ:CRME)

.

    Recent Trading Activity for Cardiome Pharma Corporation (NASDAQ:CRME)
    Shares of Cardiome Pharma Corporation closed the previous trading session at 4.75 up +0.05 1.17% with 49,644 shares trading hands.

    An ad to help with our costs